tbuckley/cabot-search huggingface dataset:
Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy
Authors: Ines Guix, Qi Liu, Miquel Angel Pujana, Patrick Ha, Josep Piulats, Isabel Linares, Ferran Guedea, Jian-Hua Mao, Ann Lazar, Jocelyn Chapman, Sue S. Yom, Alan Ashworth, Mary Helen Barcellos-Hoff
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Loss of TGFβ signaling increases error-prone alternative end-joining (alt-EJ) DNA repair. We previously translated this mechanistic relationship as TGFβ and alt-EJ gene expression signatures, which we showed are anticorrelated across cancer types. A score representing anticorrelation, βAlt, predicts patient outcome in response to genotoxic therapy. Here we sought to verify this biology in live specimens and additional datasets. Experimental Design: Human head and neck squamous carcinoma (HNSC) explants were treated in vitro to test whether the signatures report TGFβ signaling, indicated by SMAD2 phosphorylation, and unrepaired DNA damage, indicated by persistent 53BP1 foci after irradiation or olaparib. A custom NanoString assay was implemented to analyze the signatures’ expression in explants. Each signature gene was then weighted by its association with functional responses to define a modified score, βAltw, that was retested for association with response to genotoxic therapies in independent datasets. Results: Most genes in each signature were positively correlated with the expected biological response in tumor explants. Anticorrelation of TGFβ and alt-EJ signatures measured by NanoString was confirmed in explants. βAltw was significantly (P &amp;lt; 0.001) better than βAlt in predicting overall survival in response to genotoxic therapy in The Cancer Genome Atlas (TCGA) pancancer patients and in independent HNSC and ovarian cancer patient datasets. Conclusions: Association of the TGFβ and alt-EJ signatures with their biological response validates TGFβ competency as a key mediator of DNA repair that can be readily assayed by gene expression. The predictive value of βAltw supports its development to assist in clinical decision making.
Symptomatic deterioration postdual chamber cardioverter-defibrillator implantation: A retrospective, observational study Stephen V. Pavia, Alejandro Perez-Lugones, Cathy Lam, Thomas Dresing, Christopher Cole, Miguel Abreu, Bruce L. Wilkoff, Walid Saliba, Mina Chung, Patrick Tchou, Mark Niebauer, Robert Schweikert, Andrea Natale. Cleveland Clinic-Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Nobel Laureates Call for Speaking Out on Need for Animals in Research
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology
Authors: In-Seob Lee, Zhongxu Zhu, Jeeyun Lee, Joon Oh Park, Xiwei Wu, Tiffany Ong, Sierra Min Li, Xin Wang, Joseph Chao, Ajay Goel
Journal: Molecular Cancer (2022)
TCT-802 Meta-Analysis of Drug-Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Infrapopliteal Lesions in Critical Limb Ischemia
Authors: Mohammad M. Ansari, Daniel C. Garcia, Rhanderson N. Cardoso, Cesar Mendoza, Jihad A. Mustapha, Fadi Saab, Larry J. Diaz-Sandoval
Journal: Journal of the American College of Cardiology (2015)
Use of ascites CEA as a predictive value for distant metastasis in high-risk stage II and III colorectal cancer.
Authors: Chul Seung Lee, In Kyu Lee
Journal: Journal of Clinical Oncology (2022)

164 Background: Adjuvant chemotherapy in patients with high-risk stage II and III colorectal cancer prevents recurrence by eliminating minimal residual disease. However, patients who are at high risk of recurrence after completing standard adjuvant therapy are currently unknown. Although ascites CEA level has been associated with long-term oncologic outcomes, the clinical significance of ascites CEA in high-risk stage II and stage III colorectal cancer (CRC) has not yet been described. The present study aimed to determine the long-term oncologic impacts of ascites CEA level after curative colorectal cancer. Methods: A total of 191 patients with stage II/III CRC were included in this study, between January 2015 and December 2018. CEA of peritoneal fluid sampled at the beginning of each operation was analyzed. long-term oncologic outcomes were analyzed with the known risk factors for recurrence in CRC. Results: Multivariate analysis of recurrence revealed that lymphatic invasion (HR 6.0, 95% CI 1.1–32.0, p = 0.04), vascular invasion (HR 2.9, 95%CI 1.0–8.0, p = 0.04), mucinous cancer (HR 5.5, 95% CI 1.6–18.4, p = 0.006), and peritoneal fluid CEA above 5 ng/dl (OR 4.2, 95% CI 1.2–15.0, p = 0.008) were significant risk factors (Table). Peritoneal fluid cytology, microsatellite instability, cancer obstruction did not significantly impact DFS in stage II/III CRC. There were 14 patients with liver metastasis, among them, 11 patients without peritoneal metastasis; they had high ascites CEA level. While 8 patients had lung metastasis, 7 of them confirmed high ascites CEA levels. Conclusions: Our results indicate that the ascites CEA may predict as an important biomarker to identify those at risk of distant metastasis in high-risk stage II and stage III CRC patients. We suggest ascites CEA analysis might be included in patient risk assessments and oncologic prediction tools.
Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome*
Authors: Marie Roelens, Adèle de Masson, Anais Andrillon, Caroline Ram‐Wolff, Lucie Biard, Marie Boisson, Samia Mourah, Maxime Battistella, Antoine Toubert, Martine Bagot, Hélène Moins‐Teisserenc
Journal: British Journal of Dermatology (2022)

Mogamulizumab, an anti-CCR4 monoclonal antibody, has been shown to increase progression-free survival in cutaneous T-cell lymphoma.We hypothesized that besides the targeted depletion of Sézary cells (SCs), mogamulizumab may reshape the immune tumour microenvironment.Both malignant and benign compartments from 26 patients with B2 stage Sézary syndrome before mogamulizumab initiation were prospectively analysed using KIR3DL2 and TCRVβ markers, serological markers and molecular assessments of clonality.Prior to mogamulizumab, the benign subset of CD4+ T cells displayed exhausted phenotypes, with an increased gradient in programmed death-1, TIGIT, DNAM-1, CD27, CD28 and CD70 expression from age-matched controls to patients' benign CD4+ T cells and to SCs. All patients presented SCs with heterogeneous phenotypes, and differential expression of individual markers was found within distinct malignant subsets. Early complete blood response was observed in 17 of 26 patients and was associated with higher baseline CCR4 expression. A drastic decrease in benign T cells and activated regulatory T-cell counts was observed during the first 4 weeks. Long-term follow-up revealed the emergence of an immune restoration involving CD8+ and naive and stem memory CD4+ T cells, with almost complete disappearance of exhausted lymphocytes. Development of resistance or tumour escape to mogamulizumab was associated with the emergence of CCR4- SCs in blood and skin, displaying significant changes in their heterogeneity patterns, and not explained only by mutations within CCR4 coding regions.Mogamulizumab likely contributes to the restoration of efficient immunity and reshapes not only the malignant lymphocyte subset but also the benign subset. These results have potential implications for optimal therapeutic sequences and/or combinations. What is already known about this topic? Management of Sézary syndrome (SS) involves successive therapies that participate as cause and consequence in the emergence of resistant clones, on a background of immunodeficiency. We and others have reported the complex and dynamic heterogeneity of Sézary cells (SCs) during disease progression. Mogamulizumab therapy, by targeting the skin-homing receptor CCR4, mainly expressed by SCs, has been shown to increase progression-free survival in patients with SS. What does this study add? Using multicolour flow cytometry, we provide quantification of CCR4 and immune checkpoint molecules on malignant SCs and benign CD4+ T cells from patients with SS, separated using KIR3DL2 and TCRVβ expression. Mogamulizumab is not only aimed at eradicating malignant SCs but potentially contributes to the restoration of efficient immunity. Tumour escape is associated with the emergence of CCR4- SCs, not explained only by mutations within CCR4 coding regions.
A functional BCI model by the P2731 working group: psychology
Authors: Dariusz Zapała, Ali Hossaini, Mazaher Kianpour, Guillermo Sahonero-Alvarez, Aladdin Ayesh
Journal: Brain-Computer Interfaces (2021)

The development of Brain-Computer Interfaces (BCI) gathers experts and specialists in various fields, such as engineering, computer science, medicine, or cognitive neuroscience. Each of these disciplines has specific terminology, which makes mutual understanding and research collaboration difficult. The IEEE P2731 working group aims to improve communication between BCI researchers by developing a functional model and standards for terminology that can be used as a common description framework for all the involved knowledge fields. This work focuses on the vocabulary of mental processes involved in BCI communication and describes their role in a Functional Model that considers their influence on BCI performance. Finally, it presents potential uses of the proposed model.
Three-dimensional echocardiographic acquisition at 8 degree rotational intervals allows rapid volume rendered reconstruction of atrial septal defects with adequate morphological and accurate quantitative assessment Youssef F. M. Nosir, Anita Dall'Agata; Ron T van Domburg, Ad JJC Bogers and Jos RTC Roelandt. Heartcenter, Erasmus University, Rotterdam, The Netherlands, Cardiology Department, Al-Azhar University, Cairo, Egypt
Journal: Journal of the American College of Cardiology (2001)
Особливості патології органів травлення у хворих похилого та старечого віку і ефективність їх лікування
Authors: K.O. Voronin
Journal: GASTROENTEROLOGY (2013)

Автор навів у статті результати власного дослідження хворих похилого та старечого віку із хронічною абдомінальною ішемією, на тлі якої розвинулися біліарні дисфункції та функціональні закрепи. До лікування таких хворих доцільно включати тримебутин та тівортіну аспартат, що сприяють позитивній клінічній динаміці.
Eosinophilia associated with adult t‐cell leukemia: Role of interleukin 5 and granulocyte‐macrophage colony‐stimulating factor
Authors: Masao Ogata, Yuko Ogata, Kazuhiro Kohno, Noritaka Uno, Eiji Ohno, Eiichi Ohtsuka, Yoshio Saburi, Perparim Kamberi, Masaru Nasu, Hiroshi Kikuchi
Journal: American Journal of Hematology (1998)

To clarify the mechanism of eosinophilia in adult T-cell leukemia (ATL), we studied three ATL patients having marked eosinophilia. Eosinophil-predominant colony-stimulating activity was detected in the serum of one patient and in the conditioned media (CM) from cultured ATL cells from two patients. Soluble interleukin 5 (IL-5), but no interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF), was detected in sera from all patients. On the other hand, GM-CSF was produced in vitro by ATL cells from all cases, whereas detectable IL-3 and IL-5 was produced by cells from only one, suggesting that in the other two cases, the serum IL-5 was produced by the normal reacting lymphocytes. The fact that no patient showed marked neutrophilia supports the possibility that IL-5 may have a leading role in the development of eosinophilia, with GM-CSF produced by ATL cells playing a complementary role. Am. J. Hematol. 59:242–245, 1998. © 1998 Wiley-Liss, Inc.
Benign breast lumps may regress with change in diet
Authors: W. Check
Journal: JAMA (1979)

Many women with long-standing, clinically benign breast lumps may be able to reassure themselves that they do not have breast cancer by a much simpler means than breast biopsy, according to John Peter r Minton, MD, PhD, of the Department of Surgery at the Ohio State University College of Medicine. Minton has found that about two thirds of benign breast lumps disappear in women who completely eliminate all forms of methylxanthines—caffeine, theophylline, and theobromine—from their diets. Several years ago Minton found that cyclic nucleotides, which stimulate cell growth and division, are appreciably elevated in biopsy tissue from women with fibrocystic disease and fibroadenoma. He wondered whether the increased level of cyclic nucleotides might be contributing to the growth of the breast lumps and whether the increase might be due to methylxanthines. These chemicals are known to inhibit phosphodiesterase, the enzyme that catabolizes cyclic nucleotides. Reporting to the recent meeting of
AUTOMOTIVE SAFETY
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intravenous Infusions in Ipsilateral Arm After Radical Mastectomy
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Jacques Acar
Authors: Vijay Shankar Balakrishnan
Journal: The Lancet Infectious Diseases (2020)

Among many thousands of deaths, the COVID-19 pandemic has claimed the life of world renowned infectious disease expert Jacques Acar.Acar is revered for his passionate contribution to the fight against antimicrobial resistance.The polymath was hospitalised on Mar 20, 2020 upon his return from the USA after attending a congress.On March 27, 2020, Acar succumbed to the rapid evolution of COVID-19."After a life entirely dedicated to the fight against microbes, it was a virus that took him", writes his colleague Jacques Mokhbat from the Lebanese American University, in an obituary to the French daily newspaper, L'Orient-Le Jour.Born on April 13, 1931 in Dakar, Senegal, to Lebanese parents, Acar finished his secondary studies in 1948 at the Notre-Dame de Jamhour College, Lebanon, before leaving to settle in France.Acar's first interest in infectious diseases comes from the memories of times when colonial Senegal was under the grips of bubonic plague and yellow fever."The epidemic of yellow fever was still in all memories: with all the fear and the 12 months of the city quarantine-no boats and no relation with the rest of the world", recalled Acar in 2018."The discussions in my family were passionate: infectious diseases were part of the blend of nature, beauty and dread", added Acar.After graduating in 1954 from the Faculty of Medicine in Paris, Acar served as a military physician in sub-Saharan Africa for the next 3 years.His apprenticeship in various fields of medicine culminated with him becoming head of the clinic of infectious diseases at the Claude Bernard Hospital in Paris in 1962.Then his first steps into
Addendum: Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act—a Chance to Celebrate and Reflect
Journal: Journal of the American Society of Nephrology (2021)

John S. Gill, Richard N. Formica, and Barbara Murphy: Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act—a Chance to Celebrate and Reflect. J Am Soc Nephrol 32: 774–776, 2021; doi: <https://doi.org/10.1681/ASN.2020121811>. The Immuno Bill, as
ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia Michael H. Davidson, Patrick T. S. Ma, Evan Stein, Howard G. Hutchinson, Rohini Chitra, Ali Raza, Antonio Gotto, Jr.. Chicago Center for Clinical Research, Chicago, IL, Heart Health Institute Research Clinic, Calgary, Canada
Journal: Journal of the American College of Cardiology (2001)
Abstract 72: Human Vascular Smooth Muscle Gene Expression Profiling Between Incracranial and Extracranial Vasculature
Authors: Hyung-Seok Kim, Jong Tae Park, Joo Young Na, Man Seok Park
Journal: Circulation Research (2017)

Background: Intracranial arteries (IA) have unique histological, pharmacological, and pathological characteristics when compared to extracranial arteris (EA). Despite its importance, little is known about the molecular characteristics of those vessels. In this study, we carried out a genome-wide characterization on expressions of mRNAs, and performed integrative analyses in conjunction with changes of the transcriptome between IA and EA vascular smooth muscle cells. Methods: mRNA expression screening was performed from same autopsied body (n=3) using Agilent Human mRNA arrays for IA (middle cerebral a.) and EA (left ant. descending a. of coronary a.) vascular smooth muscle (vSMC) layer. Total gene expression compared with intracranial vs. extracranial vSMC. Results: As compared to EA, we identified 304 mRNA that were differentially expressed in the IA vSMC (p&lt;0.05 and fold change &gt;2), including 224 upregulated and 80 downregulated. Through this comparison we have identified angiogenesis, cell migration, cell proliferation, neurogenesis, and inflammatory response genes whose expression is enriched in IA vSMC. This analysis has identified that RAR activation, and Caveolar-mediated endocytosis signaling cascade is specifically enriched at the IA vSMC, implicating this pathway in regulating this arterial system. Conclusions: This dataset provides a resource for understanding the different arterial regulation and disease susceptibility in IA and EA, especially atherosclerosis and diabetes.Funding: This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Kim HS, NRF-2016R1A2B4008316).
Evolution of Incidence, Management, and Outcomes Over Time in Sports-Related Sudden Cardiac Arrest
Authors: Nicole Karam, Louis Pechmajou, Kumar Narayanan, Wulfran Bougouin, Ardalan Sharifzadehgan, Soraya Anys, Orianne Weizman, David Perrot, Victor Waldmann, Frankie Beganton, Marie-Cécile Perier, Julien Rischard, Thomas Loeb, Jean-Marc Agostinucci, Eric Lecarpentier, Patricia Jabre, Daniel Jost, Florence Dumas, Alain Cariou, Xavier Jouven, Eloi Marijon
Journal: Journal of the American College of Cardiology (2022)
Blurred Vision and Gastrointestinal Bleeding in a Patient With HIV
Authors: Bradley W. Christensen, Hsiao C. Li, Sergio Huerta
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal